OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one.
OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million
OmniAb (Nasdaq: OABI) shares rose roughly 13% on August 17 after the company signed a global collaboration and license agreement with Eli Lilly covering a new ion channel drug program. OmniAb will receive an upfront payment and is eligible for up to $370 million in research, development, and commercial milestones, plus tiered royalties on any resulting sales.
Neither the specific target nor the drug type was disclosed. That secrecy is standard for early discovery deals like this one.
OmniAb does not develop drugs itself. It licenses antibody-discovery technology, built around genetically engineered rats, chickens, and other animals, to pharmaceutical partners who then run their own programs. CEO Matt Foehr called Lilly an important new relationship built on OmniAb’s ion channel discovery expertise. The company earns money through upfront fees, milestones, and royalties rather than clinical trial results of its own.
The Lilly deal let OmniAb raise its full-year cash guidance to $49 million-$53 million, up from $37 million-$41 million. That is a real increase in the company’s own estimate of what it will have in the bank at year-end, not a promise about what the drug will eventually earn.
Acurx Pharmaceuticals Gains 15% as FDA Accepts CIFBEZY Brand Name for Its C. diff Antibiotic
Acurx Pharmaceuticals (Nasdaq: ACXP) shares climbed about 15% on August 17. The trigger was a name, not a trial result. The FDA conditionally accepted CIFBEZY as the proposed brand name for ibezapolstat, Acurx’s lead antibiotic candidate for Clostridioides difficile infection, and the U.S. Patent and Trademark Office allowed the federal trademark application for the same name.
Brand-name acceptance sits well before approval in the regulatory process. It establishes what a drug could be called on a label and in marketing, not whether the FDA will let it reach patients. A request for final approval of the name still gets submitted alongside the actual marketing application.
Ibezapolstat targets a bacterial enzyme largely absent in human cells and in useful gut bacteria, an approach designed to treat C. diff infection while doing less collateral damage to the microbiome than existing antibiotics. Acurx says FDA guidance from a July 13 meeting supports a path to approval based on a single Phase 3 trial covering both initial treatment and recurrence prevention, and the company has started prepping a separate Phase 2 study in patients with multiple prior recurrences.
Acurx’s market capitalization sits in the single-digit millions of dollars, among the smallest names this section covers. A regulatory step this preliminary would barely register at a larger company. Here, it moved the stock double digits.
OABI, ACXP: Forward-Looking FAQ
Not yet in a big way. The guidance bump reflects an upfront payment and near-term deal economics, not royalties, which would only arrive years from now if Lilly’s ion channel program reaches an approved drug.
Only indirectly. The brand name and trademark are administrative steps that run in parallel with drug development, not part of the efficacy or safety review. Acurx’s approval timeline still depends on completing its planned Phase 3 program, which the company has said is contingent on securing additional financing.
Sources
- BusinessWire / OmniAb IR: OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company, August 17, 2026
- FierceBiotech: Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague, August 17, 2026
- RTTNews: Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News, August 17, 2026
- PRNewswire / Acurx IR: Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company’s Brand Name for Ibezapolstat, August 17, 2026
Editorial Disclosure
This roundup is based entirely on publicly available information including named wire service releases, company press releases, and financial news reporting. Securities and entities discussed include OmniAb, Inc. (Nasdaq: OABI) and Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP). aktiego.com has not received any compensation from any company, IR firm, or third party mentioned. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. OmniAb’s collaboration terms and CEO quote are sourced to its own August 17, 2026 press release; the specific therapeutic target and modality of the Lilly program were not disclosed by either party, and the $370 million milestone figure represents a maximum potential value contingent on the program’s success, not a guaranteed payment. OmniAb’s revised cash guidance is the company’s own forward-looking estimate and is not a guarantee of actual year-end results. Acurx’s brand name and trademark milestones are sourced to its own August 17, 2026 press release; commercial use of the CIFBEZY name remains contingent on FDA approval of a future New Drug Application, which has not occurred as of publication. Acurx has stated that advancing ibezapolstat’s Phase 3 program is contingent on securing additional financing. Both companies discussed are development-stage with no FDA-approved products; their ability to reach further milestones depends on continued access to capital and future clinical or regulatory outcomes. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
